好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Tremor and Disability Outcomes After Deep Brain Stimulation for Multiple Sclerosis-associated Tremor
Multiple Sclerosis
P12 - Poster Session 12 (11:45 AM-12:45 PM)
1-014

Describe outcomes of deep brain stimulation (DBS) for MS-associated tremor in a single center and identify baseline features associated with optimal outcomes.

Tremor is common in MS and may be refractory to medications. DBS is a potential treatment, but concern for side effects and disease exacerbation limit its use. Ideal patient candidates need to be identified.
Mayo Clinic patients with MS who underwent DBS for treatment of medication-refractory tremor were retrospectively identified. Demographic, clinical, electrophysiologic, and DBS data were abstracted. Expanded Disability Status Scale (EDSS) and Fahn-Tolosa-Marin (FTM) tremor rating scale were assessed. 

We identified 18 patients who underwent DBS for MS-associated tremor including: relapsing MS, 2; secondary progressive, 8; primary progressive, 8. Median age of MS onset was 32 years (range, 21 – 65). DBS surgery was performed at median age of 49.5 years (range, 28 – 75) with a median follow-up of 2.5 years (range, 0 – 22) after. Seven patients were on MS disease modifying therapy. After surgery, no clinical relapses (0/18) or new MRI lesions (0/8) occurred. One patient had an early surgical complication (1/18). There was no change in EDSS following DBS surgery (median preoperative 6 [3 – 6.5]; postoperative 6.25 [1 – 8]; p=0.2). There was a reduction in FTM score with stimulation (preoperative median 13 [4 – 22], postoperative last follow-up 11 [2 – 16], p=0.03). There was an interaction (p<0.001) between preoperative EDSS score and tremor outcome, such that all patients with preoperative EDSS ≤3 or ≥6.5 had sustained improvement in FTM, while those with preoperative EDSS 3.5 to 6 had variability in tremor outcomes (5/8 sustained improvement).

DBS represents a potential avenue for treatment of severe tremor in MS and did not provoke inflammatory MS activity in our cohort. Baseline EDSS may be a helpful tool to identify ideal DBS candidates.

Authors/Disclosures
Samantha Banks, MD
PRESENTER
Dr. Banks has nothing to disclose.
Matthew R. Baker, PhD Dr. Baker has nothing to disclose.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.
Fiona E. Permezel, MBBS Dr. Permezel has nothing to disclose.
Lauren Jackson, MD (Mayo Clinic) Dr. Jackson has nothing to disclose.
W. O. Tobin, PhD, MBBCh, BAO, FAAN (Mayo Clinic) Dr. Tobin has received publishing royalties from a publication relating to health care.
Orhun H. Kantarci, MD Dr. Kantarci has nothing to disclose.
Mark Keegan, MD, FAAN (Mayo Clinic) Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Kai Miller (Mayo Clinic) Kai Miller has nothing to disclose.
Bryan T. Klassen, MD (Mayo Clinic) The institution of Dr. Klassen has received research support from Insightec.